EUCTR2011-000828-15-PL进行中（未招募）不适用
A Prospective, Randomized, Double-Blind Comparisonof a Long-Acting Basal Insulin Analog LY2963016 toLantus® in Adult Patients with Type 2 Diabetes Mellitus - The ELEMENT 2 Study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 792
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Have T2DM based on the disease diagnostic criteria World Health
- •Organization (WHO) classification.
- •[2] Are =18 years of age.
- •[3] Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to Visit 1, with or without Lantus. Note: use and dose of oral agents in combination with insulin must be in accordance with the local product label.
- •Patients taking metformin and who are found to have a contraindicated serum creatinine level (=1.4 mg/dL for females, =1.5 mg/dL for males, or based on country-specific label) must be willing to discontinue use of metformin at randomization.
- •Note: Sitagliptin is the only DPP-IV inhibitor currently approved for use with insulin.
- •If on two OAMs at study entry and there is a need to discontinue one of those agents due to country labeling requirements or clinical parameters, that patient would not meet entry criteria.
- •[4] Have an HbA1c =7.0% and =11.0% if insulin naïve; if previously on Lantus, then HbA1c =11.0%.
- •[5] Body mass index (BMI) =45 kg/m2.
- •[6] As determined by the investigator, are capable and willing to do the
- •? perform SMBG
- •? complete patient diaries as required
- •? use covered insulin vial and syringe according to study instructions
- •? are receptive to diabetes education
- •? comply with required study treatment and study visits.
- •[7] Have given written informed consent to participate in this study in accordance with local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[8] Have used any other insulin except Lantus, including commercial and investigational insulins within the previous 30 days.
- •[9] Have been exposed to a biosimilar insulin glargine within the previous 90 days.
- •[10] Have a history of taking basal bolus therapy or who, in the investigator's opinion, require mealtime insulin in order to achieve target control.
- •[11] Have used short-acting glucagon like peptide (GLP-1) agonist (eg, exenatide) or long-acting GLP-1 agonist (eg, liraglutide) within the previous 90 days.
- •[12] Have used pramlintide (eg, Symlin®) within the previous 30 days.
- •[13] Have excessive insulin resistance at study entry (total insulin dose =1.5 U/kg).
- •[14] Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.
- •[15] Have known hypersensitivity or allergy to Lantus or its excipients.
- •[16] Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy at pharmacological doses (excluding topical, intra-articular, intraocular, or inhaled preparations and physiologic replacement doses for adrenal deficiency) or have received such therapy within 4 weeks immediately preceding Visit 1.
- •[17] Have obvious signs or symptoms, or laboratory evidence, of liver disease (alanine aminotransferase [ALT]; or aspartate minotransferase [AST] greater than 2.5 times the upper limit of the reference range, as defined by the central laboratory); or albumin value remarkably above or below the normal reference range, as defined by the central laboratory.
- •[18] Have one of the following concomitant diseases: significant cardiac (eg, congestive heart failure Class III or IV) or gastrointestinal disease (eg, significant gastroparesis).
- •[19] Have a history of renal transplantation, are currently receiving renal dialysis or have a serum creatinine greater than 2.0 mg/dL
- •[20] Have had a blood transfusion or severe blood loss within 3 months prior to Visit 1 or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
- •[21] Patients with active cancer or personal history of cancer within the previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ).
- •[22] Are investigator-site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •[23] Have any other condition (including known drug or alcohol abuse or
- •psychiatric disorder) that precludes the patient from following and completing
- •the protocol.
- •[24] Are Lilly employees.
- •[25] Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device other than LY2963016, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- •[26] Have previously completed or withdrawn from this study.
- •[27] Are pregnant or intend to become pregnant during the course of the study or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.
- •[28] Women who are breastfeeding.
研究者
相似试验
进行中（未招募）
1 期
A study to compare an investigational ultra-rapid insulin, LY900014 with insulin lispro in children with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2018-002371-18-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER751
进行中（未招募）
1 期
A study to compare an investigational ultra-rapid insulin, LY900014 with another mealtime insulin, Fiasp when both are used along with a long-acting insulin in people with type 1 diabetesDiabetes Mellitus, Type 1EUCTR2017-003399-30-ATEli Lilly and Company632
进行中（未招募）
1 期
A study to compare an investigational ultra-rapid insulin, LY900014 with insulin lispro in children with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2018-002371-18-GBEli Lilly and Company708
进行中（未招募）
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 20.1Level: LLTClassification code 10020639Term: HyperglycemiaSystem Organ Class: 100000004861Type 1 DiabetesEUCTR2015-005356-99-PLEli Lilly and Company1,392
进行中（未招募）
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 19.1 Level: LLT Classification code 10020639 Term: Hyperglycemia System Organ Class: 100000004861Type 1 DiabetesEUCTR2015-005356-99-ESilly S.A.1,328